RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain October 4, 2021
Insights into China’s Pharmaceutical Industry Trends from a 2,000-strong Industry Conference September 30, 2021 Life Science
Hemostemix Announces Closing of First Tranche of Unit Private Placement September 21, 2021 Life Science
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021 Life Science
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years September 14, 2021 Life Science
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies July 7, 2021 Life Science
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results July 6, 2021 Life Science
Increasing Sales and Expanding Markets: Learn about Milestone’s diagnostic and therapeutic injection technologies June 7, 2021 Life Science
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record May 31, 2021 Life Science
